HARMONI-GI1
Start here
Ivonescimab, a PD-1/VEGF bispecific antibody, combined with chemotherapy met the primary endpoint of overall survival as a first-line treatment for advanced biliary tract cancer in the Phase 3 HARMONi-GI1 trial. Results were presented at the 2026 ESMO Congress. The regimen was tested head-to-head against durvalumab plus chemotherapy, a current standard immunotherapy-based combination. The positive overall survival result positions the ivonescimab regimen as a potential new first-line option for this cancer, where advanced disease has historically been difficult to treat. Detailed survival figures from the presentation have not yet been reported on this page.
Written by a model from the reports · updated 1 hour ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickIvonescimab posts 14.9-month overall survival in HARMONi-GI1 head-to-head biliary tract cancer trial
Ivonescimab achieved a median overall survival of 14.9 months in the Phase III HARMONi-GI1 head-to-head study in biliary tract cancer, with a statistically significant positive OS result. It is the first global Phase III study in biliary tract cancer to show significant OS benefit against a PD-L1 antibody plus chemotherapy control; the TOPAZ-1 study previously established durvalumab plus gemcitabine and cisplatin as first-line standard of care.
- mp.weixin.qq.comPickPD-1/VEGF Bispecific Ivonescimab Plus Chemotherapy Meets Overall Survival Primary Endpoint in Phase 3 HARMONi-GI1 Biliary Tract Cancer Trial
Phase 3 HARMONi-GI1 data presented at the 2026 ESMO Congress show that ivonescimab combined with chemotherapy met the overall survival primary endpoint as first-line treatment for advanced biliary tract cancer. The regimen was compared head-to-head against durvalumab plus chemotherapy.
Heat trend for this story
Heat now 172·Peak in the comparable set 195 (Oct 26 06:00)·Change over 24h in the comparable set +1811%·Participants now 26
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.